Merriman Curhan Ford Equity Research on
Starpharma Holdings Ltd. (OTCQX: SPHRY)

Thank you for your interest in Merriman Curhan Ford’s U.S. equity research on Starpharma Holdings Ltd. (OTCQX: SPHRY). Please fill out and submit the electronic form below to immediately receive the research.

Merriman Curhan Ford initiated research coverage on Starpharma in June 2007, rating its American Depositary Receipts (OTCQX: SPHRY) as a buy. The U.S. based investment bank also acts as the company’s Investment Bank Principal American Liaison (PAL) on the International OTCQX listing service.

Already registered: click here

 

Please provide the following information to complete your registation.
An asterisk (*) indicates a required field.
*First Name:
*Last Name:
*E-mail Address:
*Phone Number: 
*Financial Institution:
*A Current SPHRY Investor:             

 
   • Alter NRG, Corp.
   • CMA Corporation, Ltd.
   • Helix Biopharma, Corp.
   • Intec, Ltd.
   • Linc Energy, Ltd.
   • Omnitek Engineering, Corp.
   • Pink OTC Markets, Inc.
   • QRxPharma, Ltd.
     



Locations | Privacy Statement | Business Continuity | Terms/Conditions | Disclosures | Third Party Disclosure | NASDAQ:MERR
©2010 | Merriman Curhan Ford & Co | All Rights Reserved | Member FINRA/SIPC